Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market Growth Outlook Reveals A CAGR Of 9.8% And A Market Value Of $5.02 Billion By 2030
Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market Growth Analysis: How Will Revenue Expand During The Forecast Period?
The market for calcitonin gene-related peptide (CGRP) inhibitors has experienced robust expansion over the past few years. Its value is projected to rise from $3.14 billion in 2025 to $3.45 billion in 2026, reflecting a compound annual growth rate (CAGR) of 9.9%. This past growth has been driven by factors such as the increasing incidence of migraine conditions, the shortcomings of traditional migraine treatments, stronger clinical evidence supporting the CGRP pathway, greater adoption by neurologists, and supportive reimbursement policies in developed economies.
The market for calcitonin gene-related peptide (CGRP) inhibitors is projected to experience robust expansion over the coming years. By 2030, it is anticipated to reach $5.02 billion, reflecting a compound annual growth rate (CAGR) of 9.8%. This forecasted growth can be linked to several factors: the enlarging pool of patients suffering from chronic migraines, the development of a broader pipeline for oral CGRP inhibitors, a growing need for sustained migraine prevention, better patient adherence to targeted treatment options, and enhanced market access in developing regions. Notable trends expected to shape the forecast period encompass the rising uptake of targeted migraine therapies, a growing emphasis on preventive approaches to migraine care, an increased preference for non-opioid pain relief strategies, the advancement of oral small-molecule CGRP inhibitors, and heightened awareness coupled with better diagnostic rates for chronic migraines.
Download A Free Sample Report For Comprehensive Market Insights:
#Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market Growth Factors: Which Forces Are Supporting Market Expansion?
The rising incidence of migraine is anticipated to drive forward the calcitonin gene-related peptide (CGRP) inhibitors market. Migraine is characterized by intense headache episodes, frequently causing throbbing pain on one side of the head, accompanied by symptoms such as nausea, vomiting, and heightened sensitivity to light and sound. This increasing prevalence is linked to elevated stress levels, as chronic stress activates specific neural pathways. CGRP inhibitors offer a targeted preventive approach for migraine management, compatible with both acute and chronic treatment plans, by effectively blocking CGRP receptors to reduce headache frequency and severity, thereby enhancing patient well-being and daily functioning. In January 2023, data from the National Library of Medicine, a US-based health information institution, revealed that the global migraine prevalence ranges between 14% and 15%, accounting for 4.9% of the worldwide disease burden. Consequently, the growing prevalence of migraine is fueling the expansion of the CGRP inhibitors market.
Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market Segment Analysis Highlighting Growth Areas
The calcitonin gene-related peptide (cgrp) inhibitors market covered in this report is segmented –
1) By Type Of Inhibitor: Monoclonal Antibodies, Small Molecules, Peptides
2) By Mechanism Of Action: Anti-Calcitonin Gene-Related Peptide (CGRP) Ligand, Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist
3) By Route of Administration: Oral, Nasal, Intravenous
4) By Treatment: Preventive Migraine Treatment, Acute Migraine Treatment
5) By End User: Hospitals, Specialty Clinics, Mail Order Pharmacies, Retail Pharmacies
Subsegments:
1) By Monoclonal Antibodies: Erenumab (Aimovig), Eptinezumab (Vyepti), Fremanezumab (Ajovy), Galcanezumab (Emgality)
2) By Small Molecules: Ubrogepant, Rimegepant, Atogepant, Zavegepant
3) By Peptides: Calcitonin Gene-Related Peptide (CGRP) Antagonist Peptides, Modified Calcitonin Gene-Related Peptide (CGRP) Analogs, Intranasal Peptide Formulations, Peptide-Based Delivery Systems
Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market Industry Trends: What Changes Are Reshaping Demand?
Key players in the calcitonin gene-related peptide (CGRP) inhibitors market are concentrating their efforts on creating groundbreaking products aimed at obtaining regulatory approvals, such as CGRP receptor antagonists designed to improve migraine treatment effectiveness, broadening the range of therapeutic uses, and providing more patient-friendly delivery methods like oral and intranasal forms. A CGRP receptor antagonist is a medication that blocks the CGRP receptor to interrupt pain signals associated with migraines. As an example, in April 2023, AbbVie Inc., a biotechnology firm based in the United States, secured approval from the U.S. Food and Drug Administration (FDA) for QULIPTA (atogepant) in the management of chronic migraine among adults. QULIPTA is an oral CGRP receptor antagonist that functions by obstructing CGRP receptors, which play a role in migraine mechanisms, thus aiding in the prevention of migraine episodes.
Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market Leading Companies: Who Holds Significant Market Presence?
Major companies operating in the calcitonin gene-related peptide (cgrp) inhibitors market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bristol Myers Squibb Company, AstraZeneca plc, Novartis AG, Eli Lilly and Company, Amgen Inc., Otsuka Holdings Co. Ltd., Teva Pharmaceutical Industries Ltd., H. Lundbeck A/S, Kissei Pharmaceutical Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., Shin Nippon Biomedical Laboratories Ltd., Sosei Group Corporation, Nuvie Bio Inc., Vaxxinity Inc., Acherx LLC, AfaSci Inc.
Access The Complete Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market Report:
Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market Regional Analysis And Leading Geography
North America was the largest region in the calcitonin gene-related peptide (CGRP) inhibitors market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the calcitonin gene-related peptide (cgrp) inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
